{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:48:40Z","timestamp":1787906920371,"version":"build-2784847793"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research Bulletin"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.brainresbull.2020.12.017","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T11:39:26Z","timestamp":1609328366000},"page":"100-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Research on developing drugs for Parkinson's disease"],"prefix":"10.1016","volume":"168","author":[{"given":"Cheng-lu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-wen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-he","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 9","key":"10.1016\/j.brainresbull.2020.12.017_bib0005","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/brain\/awv179","article-title":"Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations","volume":"138","author":"Alcalay","year":"2015","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.brainresbull.2020.12.017_bib0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1089\/ars.2013.5814","article-title":"Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement","volume":"23","author":"Altenhofer","year":"2015","journal-title":"Antioxid. Redox Signal."},{"issue":"8","key":"10.1016\/j.brainresbull.2020.12.017_bib0015","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","article-title":"Pioglitazone in early Parkinson\u2019s disease: a phase 2, multicentre, double-blind, randomised trial","volume":"14","author":"Anon","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","article-title":"Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry","volume":"45","author":"Antonini","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0025","doi-asserted-by":"crossref","first-page":"15446","DOI":"10.1038\/s41598-018-33921-x","article-title":"Reduced glucocerebrosidase activity in monocytes from patients with Parkinson\u2019s disease","volume":"8","author":"Atashrazm","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","article-title":"Insulin resistance and Parkinson\u2019s disease: A new target for disease modification?","volume":"145-146","author":"Athauda","year":"2016","journal-title":"Prog. Neurobiol."},{"issue":"5","key":"10.1016\/j.brainresbull.2020.12.017_bib0035","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"10103","key":"10.1016\/j.brainresbull.2020.12.017_bib0040","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"Pt 2","key":"10.1016\/j.brainresbull.2020.12.017_bib0045","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2013","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.brainresbull.2020.12.017_bib0050","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.brainresbull.2020.12.017_bib0055","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1471-4159.2008.05254.x","article-title":"Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson\u2019s disease","volume":"105","author":"Bar-On","year":"2008","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13024-017-0225-5","article-title":"NADPH oxidases in Parkinson\u2019s disease: a systematic review","volume":"12","author":"Belarbi","year":"2017","journal-title":"Mol. Neurodegener."},{"issue":"8","key":"10.1016\/j.brainresbull.2020.12.017_bib0065","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mds.25920","article-title":"The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model","volume":"29","author":"Bezard","year":"2014","journal-title":"Mov. Disord."},{"issue":"514","key":"10.1016\/j.brainresbull.2020.12.017_bib0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau6870","article-title":"A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson\u2019s disease","volume":"11","author":"Burbulla","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.brainresbull.2020.12.017_bib0075","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3233\/JPD-171203","article-title":"Simvastatin as a potential disease-modifying therapy for patients with parkinson\u2019s disease: rationale for clinical trial, and current progress","volume":"7","author":"Carroll","year":"2017","journal-title":"J. Parkinsons Dis."},{"issue":"10","key":"10.1016\/j.brainresbull.2020.12.017_bib0080","doi-asserted-by":"crossref","first-page":"e029740","DOI":"10.1136\/bmjopen-2019-029740","article-title":"Simvastatin as a neuroprotective treatment for Parkinson\u2019s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study","volume":"9","author":"Carroll","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejphar.2017.10.023","article-title":"A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties","volume":"818","author":"Chan","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.brainresbull.2020.12.017_bib0090","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nrd.2018.136","article-title":"Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs","volume":"17","author":"Charvin","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.brainresbull.2020.12.017_bib0095","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jcph.1008","article-title":"Repeated-dose oral N-Acetylcysteine in parkinson\u2019s disease: pharmacokinetics and effect on brain glutathione and oxidative stress","volume":"58","author":"Coles","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0100","article-title":"NS-Park\/F-CRIN Network. A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Phase IIa Trial to Evaluate the Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson\u2019s Disease [abstract]","volume":"33","author":"Corvol","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pneurobio.2016.07.002","article-title":"Expanding the repertoire of L-DOPA\u2019s actions: a comprehensive review of its functional neurochemistry","volume":"151","author":"De Deurwaerd\u00e8re","year":"2017","journal-title":"Prog. Neurobiol."},{"issue":"11","key":"10.1016\/j.brainresbull.2020.12.017_bib0110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrneurol.2013.209","article-title":"NURR1 in Parkinson disease--from pathogenesis to therapeutic potential","volume":"9","author":"Decressac","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.brainresbull.2020.12.017_bib0115","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/mds.25882","article-title":"Gut feelings about smoking and coffee in Parkinson\u2019s disease","volume":"29","author":"Derkinderen","year":"2014","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.brainresbull.2020.12.017_bib0120","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1570159X14666151120123025","article-title":"Current pharmaceutical treatments and alternative therapies of parkinson\u2019s disease","volume":"14","author":"Dong","year":"2016","journal-title":"Curr. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.brainresbull.2020.12.017_bib0125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/cns.12536","article-title":"Nurr1-based therapies for parkinson\u2019s disease","volume":"22","author":"Dong","year":"2016","journal-title":"CNS Neurosci. Ther."},{"issue":"10","key":"10.1016\/j.brainresbull.2020.12.017_bib0130","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1080\/15548627.2015.1086055","article-title":"GBA deficiency promotes SNCA\/alpha-synuclein accumulation through autophagic inhibition by inactivated PPP2A","volume":"11","author":"Du","year":"2015","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.brainresbull.2020.12.017_bib0135","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/mds.25098","article-title":"Donepezil in Parkinson\u2019s disease dementia: a randomized, double-blind efficacy and safety study","volume":"27","author":"Dubois","year":"2012","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.brainresbull.2020.12.017_bib0140","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s disease","volume":"14","author":"Fasano","year":"2015","journal-title":"Lancet Neurol."},{"issue":"16","key":"10.1016\/j.brainresbull.2020.12.017_bib0145","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1073\/pnas.88.16.7238","article-title":"Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes","volume":"88","author":"Ferre","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.brainresbull.2020.12.017_bib0150","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/ar050073t","article-title":"The aggregation and fibrillation of alpha-synuclein","volume":"39","author":"Fink","year":"2006","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0155","series-title":"Glycolysis As a Therapeutic Target for Parkinson\u2019s Disease","author":"Foltynie","year":"2019"},{"issue":"9","key":"10.1016\/j.brainresbull.2020.12.017_bib0160","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","article-title":"Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the mptp primate model of parkinson disease","volume":"63","author":"Fox","year":"2006","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.brainresbull.2020.12.017_bib0165","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-016-0386-8","article-title":"Novel levodopa formulations for parkinson\u2019s disease","volume":"30","author":"Freitas","year":"2016","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.brainresbull.2020.12.017_bib0170","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1212\/WNL.0000000000004888","article-title":"Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease","volume":"90","author":"Fujimaki","year":"2018","journal-title":"Neurology"},{"issue":"6369","key":"10.1016\/j.brainresbull.2020.12.017_bib0175","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.aan6160","article-title":"Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers","volume":"358","author":"Fusco","year":"2017","journal-title":"Science"},{"issue":"16 Supplement","key":"10.1016\/j.brainresbull.2020.12.017_bib0180","first-page":"S4","article-title":"ND0612, a novel liquid formulation of levodopa\/carbidopa for subcutaneous infusion in patients with Parkinson\u2019s disease achieves stable levodopa plasma levels when administered in low and high doses (S4.002)","volume":"88","author":"Giladi","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1021\/jm800961g","article-title":"Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines","volume":"52","author":"Gillespie","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-pharmtox-011613-135937","article-title":"Environmental toxins and Parkinson\u2019s disease","volume":"54","author":"Goldman","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0195","doi-asserted-by":"crossref","DOI":"10.1002\/ana.25557","article-title":"Increased immune activation by pathologic alpha-synuclein in Parkinson\u2019s Disease","author":"Grozdanov","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0200","first-page":"104621","article-title":"Exercise, diet and stress as modulators of gut microbiota: implications for neurodegenerative diseases","author":"Gubert","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.brainresbull.2020.12.017_bib0205","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40261-018-0632-6","article-title":"A phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel dopamine D1 receptor partial agonist, PF-06669571, in subjects with idiopathic parkinson\u2019s disease","volume":"38","author":"Gurrell","year":"2018","journal-title":"Clin. Drug Investig."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0210","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-017-1018-z","article-title":"Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes","volume":"14","author":"Gustafsson","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0215","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nbd.2014.03.004","article-title":"Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson\u2019s disease","volume":"67","author":"Gyoneva","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.expneurol.2017.11.010","article-title":"Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease","volume":"300","author":"Harms","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.parkreldis.2016.08.020","article-title":"Adjunctive preladenant: a placebo-controlled, dose-finding study in Japanese patients with Parkinson\u2019s disease","volume":"32","author":"Hattori","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/j.brainresbull.2020.12.017_bib0230","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","article-title":"Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson\u2019s disease and motor fluctuations: a phase 3 randomised, double-blind trial","volume":"12","author":"Hauser","year":"2013","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.brainresbull.2020.12.017_bib0235","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.freeradbiomed.2011.01.019","article-title":"Mitochondrial complex I impairment in leukocytes from type 2 diabetic patients","volume":"50","author":"Hernandez-Mijares","year":"2011","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.brainresbull.2020.12.017_bib0240","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000338774","article-title":"Cholinergic deficit and response to donepezil therapy in Parkinson\u2019s disease with dementia","volume":"68","author":"Hiraoka","year":"2012","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.08.023","article-title":"Miro1 marks parkinson\u2019s disease subset and Miro1 reducer rescues neuron loss in parkinson\u2019s models","author":"Hsieh","year":"2019","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.brainresbull.2020.12.017_bib0250","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1471-4159.2009.06011.x","article-title":"Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys","volume":"109","author":"Huang","year":"2009","journal-title":"J. Neurochem."},{"issue":"11","key":"10.1016\/j.brainresbull.2020.12.017_bib0255","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0028-3908(96)00100-1","article-title":"Dopamine receptors and brain function","volume":"35","author":"Jaber","year":"1996","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.brainresbull.2020.12.017_bib0260","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneurol.2017.140","article-title":"Parkinson disease: exenatide - a drug for diabetes and Parkinson disease?","volume":"13","author":"Jankovic","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.brainresbull.2020.12.017_bib0265","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-Synuclein monoclonal antibody, in patients with parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0270","doi-asserted-by":"crossref","first-page":"4578462","DOI":"10.1155\/2019\/4578462","article-title":"Current progress of mitochondrial quality control pathways underlying the pathogenesis of parkinson\u2019s disease","volume":"2019","author":"Jiang","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"9996","key":"10.1016\/j.brainresbull.2020.12.017_bib0275","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.brainresbull.2020.12.017_bib0280","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bbadis.2017.02.002","article-title":"Nicotine slows down oligomerisation of \u03b1-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson\u2019s disease","volume":"1863","author":"Kardani","year":"2017","journal-title":"Biochimica et Biophysica Acta (BBA) \u2013 Mol. Basis Dis."},{"issue":"28","key":"10.1016\/j.brainresbull.2020.12.017_bib0285","doi-asserted-by":"crossref","first-page":"8756","DOI":"10.1073\/pnas.1509742112","article-title":"Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson\u2019s disease","volume":"112","author":"Kim","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0290","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1385\/MN:30:1:077","article-title":"Perspectives on MAO-B in aging and neurological disease: where do we go from here?","volume":"30","author":"Kumar","year":"2004","journal-title":"Mol. Neurobiol."},{"issue":"s1","key":"10.1016\/j.brainresbull.2020.12.017_bib0295","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.3233\/JPD-179006","article-title":"The MPTP story","volume":"7","author":"Langston","year":"2017","journal-title":"J. Parkinsons Dis."},{"issue":"4587","key":"10.1016\/j.brainresbull.2020.12.017_bib0300","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0305","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of alpha-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0310","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.25742","article-title":"Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson\u2019s disease","volume":"29","author":"LeWitt","year":"2014","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.brainresbull.2020.12.017_bib0315","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/mds.26611","article-title":"A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson\u2019s disease","volume":"31","author":"LeWitt","year":"2016","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.brainresbull.2020.12.017_bib0320","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7638","key":"10.1016\/j.brainresbull.2020.12.017_bib0325","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0330","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.mcn.2017.04.009","article-title":"Extensive uptake of \u03b1-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage","volume":"82","author":"Lindstr\u00f6m","year":"2017","journal-title":"Mol. Cell. Neurosci."},{"issue":"9","key":"10.1016\/j.brainresbull.2020.12.017_bib0335","doi-asserted-by":"crossref","first-page":"20704","DOI":"10.3390\/ijms160920704","article-title":"Mitochondria: a therapeutic target for parkinson\u2019s disease?","volume":"16","author":"Luo","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0340","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40035-017-0099-z","article-title":"Current understanding of the molecular mechanisms in Parkinson\u2019s disease: targets for potential treatments","volume":"6","author":"Maiti","year":"2017","journal-title":"Transl. Neurodegener."},{"issue":"7766","key":"10.1016\/j.brainresbull.2020.12.017_bib0345","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1405-y","article-title":"Intestinal infection triggers Parkinson\u2019s disease-like symptoms in Pink1(-\/-) mice","volume":"571","author":"Matheoud","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0350","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-Synuclein form a bidirectional pathogenic loop in Synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.brainresbull.2020.12.017_bib0355","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/cn400100f","article-title":"Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson\u2019s disease","volume":"4","author":"McFarland","year":"2013","journal-title":"ACS Chem. Neurosci."},{"issue":"Pt 5","key":"10.1016\/j.brainresbull.2020.12.017_bib0360","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.brainresbull.2020.12.017_bib0365","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice","volume":"80","author":"Migdalska-Richards","year":"2016","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.brainresbull.2020.12.017_bib0370","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.25418","article-title":"Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson\u2019s disease","volume":"28","author":"Mizuno","year":"2013","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.brainresbull.2020.12.017_bib0375","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/mp.2016.187","article-title":"Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer\u2019s disease therapy","volume":"23","author":"Moriguchi","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0380","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"issue":"25","key":"10.1016\/j.brainresbull.2020.12.017_bib0385","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.2174\/138161210793176527","article-title":"Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders","volume":"16","author":"Naoi","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.brainresbull.2020.12.017_bib0390","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.23687","article-title":"Meta-analysis of early nonmotor features and risk factors for Parkinson disease","volume":"72","author":"Noyce","year":"2012","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.brainresbull.2020.12.017_bib0395","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.26941","article-title":"A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson\u2019s disease","volume":"32","author":"Olanow","year":"2017","journal-title":"Mov. Disord."},{"issue":"19","key":"10.1016\/j.brainresbull.2020.12.017_bib0400","doi-asserted-by":"crossref","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","article-title":"Diabetes mellitus and Parkinson disease","volume":"90","author":"Pagano","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0405","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2016.06.002","article-title":"Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson\u2019s disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs","volume":"29","author":"Palhagen","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"issue":"3","key":"10.1016\/j.brainresbull.2020.12.017_bib0410","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1124\/jpet.300.3.958","article-title":"A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells","volume":"300","author":"Perry","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.brainresbull.2020.12.017_bib0415","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/13543784.2014.931370","article-title":"Mavoglurant as a treatment for Parkinson\u2019s disease","volume":"23","author":"Petrov","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.brainresbull.2020.12.017_bib0420","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","article-title":"The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson\u2019s disease","volume":"85","author":"Pickrell","year":"2015","journal-title":"Neuron"},{"issue":"17","key":"10.1016\/j.brainresbull.2020.12.017_bib0425","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1212\/WNL.0000000000004568","article-title":"Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): a randomized trial","volume":"89","author":"Postuma","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.brainresbull.2020.12.017_bib0430","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/pr.110.003269","article-title":"alpha6beta2* and alpha4beta2* nicotinic acetylcholine receptors as drug targets for Parkinson\u2019s disease","volume":"63","author":"Quik","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0435","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.phrs.2016.11.013","article-title":"Metabotropic glutamate receptors and neurodegenerative diseases","volume":"115","author":"Ribeiro","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.brainresbull.2020.12.017_bib0440","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tibs.2015.02.003","article-title":"Mitochondrial dysfunction and mitophagy in Parkinson\u2019s: from familial to sporadic disease","volume":"40","author":"Ryan","year":"2015","journal-title":"Trends Biochem. Sci."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0445","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2009.01.038","article-title":"A Nurr1\/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death","volume":"137","author":"Saijo","year":"2009","journal-title":"Cell"},{"issue":"10 Supplement","key":"10.1016\/j.brainresbull.2020.12.017_bib0450","first-page":"I7","article-title":"IRX4204: a clinical stage, potent, and highly selective RXR agonist compound is brain penetrant, and promotes differentiation of oligodendrocyte precursor cells (OPCs) in vitro (I7-2.001)","volume":"82","author":"Sanders","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.brainresbull.2020.12.017_bib0455","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.brainresbull.2020.12.017_bib0460","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1073\/pnas.1817885116","article-title":"The glutathione cycle shapes synaptic glutamate activity","volume":"116","author":"Sedlak","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0465","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.neuropharm.2018.04.008","article-title":"Nurr1: a vital participant in the TLR4-NF-\u03baB signal pathway stimulated by \u03b1-synuclein in BV-2 cells","volume":"144","author":"Shao","year":"2019","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.brainresbull.2020.12.017_bib0470","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1007\/s12035-015-9267-2","article-title":"Apocyanin, a microglial NADPH oxidase inhibitor prevents dopaminergic neuronal degeneration in lipopolysaccharide-induced parkinson\u2019s disease model","volume":"53","author":"Sharma","year":"2016","journal-title":"Mol. Neurobiol."},{"issue":"11","key":"10.1016\/j.brainresbull.2020.12.017_bib0475","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","article-title":"The link between the GBA gene and parkinsonism","volume":"11","author":"Sidransky","year":"2012","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0480","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0300-483X(88)90169-2","article-title":"Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"49","author":"Singer","year":"1988","journal-title":"Toxicology"},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0485","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2013.05.001","article-title":"Glutathione metabolism and Parkinson\u2019s disease","volume":"62","author":"Smeyne","year":"2013","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0490","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrn2039","article-title":"How to make a mesodiencephalic dopaminergic neuron","volume":"8","author":"Smidt","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"issue":"10","key":"10.1016\/j.brainresbull.2020.12.017_bib0495","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/mds.104","article-title":"Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson\u2019s blood cells","volume":"33","author":"Smith","year":"2018","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.brainresbull.2020.12.017_bib0500","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1073\/pnas.1616874114","article-title":"Nurr1:RXRalpha heterodimer activation as monotherapy for Parkinson\u2019s disease","volume":"114","author":"Spathis","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/j.brainresbull.2020.12.017_bib0505","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1212\/WNL.0000000000004003","article-title":"Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease","volume":"88","author":"Stocchi","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.brainresbull.2020.12.017_bib0510","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","article-title":"Levodopa in parkinson\u2019s disease: current status and future developments","volume":"16","author":"Tambasco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"issue":"10","key":"10.1016\/j.brainresbull.2020.12.017_bib0515","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1212\/01.wnl.0000256374.50227.4b","article-title":"Temporal relationship between cigarette smoking and risk of Parkinson disease","volume":"68","author":"Thacker","year":"2007","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.brainresbull.2020.12.017_bib0520","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2A trial of the novel mGluR5-Negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in parkinson\u2019s disease","volume":"31","author":"Tison","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0525","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fnmol.2018.00165","article-title":"Simvastatin inhibits activation of NADPH Oxidase\/p38 MAPK pathway and enhances expression of antioxidant protein in parkinson disease models","volume":"11","author":"Tong","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.brainresbull.2020.12.017_bib0530","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"\u0391-synuclein immunotherapy blocks uptake and templated propagation of misfolded \u03b1-Synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.brainresbull.2020.12.017_bib0535","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/mds.26585","article-title":"Mavoglurant in Parkinson\u2019s patients with l-Dopa-induced dyskinesias: two randomized phase 2 studies","volume":"31","author":"Trenkwalder","year":"2016","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.brainresbull.2020.12.017_bib0540","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/mds.26219","article-title":"Gastroretentive carbidopa\/levodopa, DM-1992, for the treatment of advanced Parkinson\u2019s disease","volume":"30","author":"Verhagen Metman","year":"2015","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0545","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ene.13474","article-title":"High-dose transdermal nicotine in Parkinson\u2019s disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study","volume":"25","author":"Villafane","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.brainresbull.2020.12.017_bib0550","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","article-title":"The Lewy body in Parkinson\u2019s disease and related neurodegenerative disorders","volume":"47","author":"Wakabayashi","year":"2013","journal-title":"Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.brainresbull.2020.12.017_bib0555","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/glia.22724","article-title":"Subpicomolar diphenyleneiodonium inhibits microglial NADPH oxidase with high specificity and shows great potential as a therapeutic agent for neurodegenerative diseases","volume":"62","author":"Wang","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0560","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","article-title":"Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target","volume":"4","author":"Wang","year":"2015","journal-title":"Transl. Neurodegener."},{"issue":"Pt 5","key":"10.1016\/j.brainresbull.2020.12.017_bib0565","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/brain\/awv034","article-title":"Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson\u2019s disease models","volume":"138","author":"Wang","year":"2015","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.brainresbull.2020.12.017_bib0570","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.brainresbull.2020.12.017_bib0575","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.18632\/oncotarget.7191","article-title":"Selective brain penetrable Nurr1 transactivator for treating Parkinson\u2019s disease","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.brainresbull.2020.12.017_bib0580","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresbull.2020.12.017_bib0585","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev-physiol-022516-034406","article-title":"Microglia in physiology and disease","volume":"79","author":"Wolf","year":"2017","journal-title":"Annu. Rev. Physiol."},{"issue":"10","key":"10.1016\/j.brainresbull.2020.12.017_bib0590","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1073\/pnas.0937239100","article-title":"NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson\u2019s disease","volume":"100","author":"Wu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.brainresbull.2020.12.017_bib0595","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/cns.12053","article-title":"Simvastatin induces neuroprotection in 6-OHDA-lesioned PC12 via the PI3K\/AKT\/caspase 3 pathway and anti-inflammatory responses","volume":"19","author":"Xu","year":"2013","journal-title":"CNS Neurosci. Ther."},{"issue":"6","key":"10.1016\/j.brainresbull.2020.12.017_bib0600","doi-asserted-by":"crossref","first-page":"e20945","DOI":"10.1371\/journal.pone.0020945","article-title":"Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses","volume":"6","author":"Yan","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.brainresbull.2020.12.017_bib0605","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ana.21313","article-title":"Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms","volume":"63","author":"Yu","year":"2008","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.brainresbull.2020.12.017_bib0610","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.brainresbull.2020.12.017_bib0615","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12906-016-1525-y","article-title":"The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor","volume":"17","author":"Zarmouh","year":"2017","journal-title":"BMC Complement. Altern. Med."},{"issue":"52","key":"10.1016\/j.brainresbull.2020.12.017_bib0620","doi-asserted-by":"crossref","first-page":"52ra73","DOI":"10.1126\/scitranslmed.3001059","article-title":"PGC-1alpha, a potential therapeutic target for early intervention in Parkinson\u2019s disease","volume":"2","author":"Zheng","year":"2010","journal-title":"Sci. Transl. Med."}],"container-title":["Brain Research Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0361923020307346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0361923020307346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:42:41Z","timestamp":1759783361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0361923020307346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":124,"alternative-id":["S0361923020307346"],"URL":"https:\/\/doi.org\/10.1016\/j.brainresbull.2020.12.017","relation":{},"ISSN":["0361-9230"],"issn-type":[{"value":"0361-9230","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research on developing drugs for Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Brain Research Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainresbull.2020.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}